|
1.
|
GP StathopoulosT BoulikasLipoplatin
formulation review articleJ Drug DelivAug292011(Epub ahead of
print)
|
|
2.
|
Non-Small-Cell Lung Cancer Collaborative
GroupChemotherapy in non-small-cell lung cancer, a meta-analysis
using updated data on individual patients from 52 randomised
clinical trialsBMJ311899909199510.1136/bmj.311.7010.8997580546
|
|
3.
|
FA ShepherdJ DanceyA ArnoldPhase II study
of pemetrexed disodium, a multitargeted antifolate and cisplatin as
first line therapy in patients with advanced non-small-cell lung
cancerCancer92595600200110.1002/1097-0142(20010801)92:3%3C595::AID-CNCR1359%3E3.0.CO;2-D11505404
|
|
4.
|
A ArdizzoniL BoniM TisseoCisplatin versus
carboplatin-based chemotherapy in first line treatment of advanced
non-small-cell lung cancer: an individual patient data
meta-analysisJ Natl Cancer
Inst99847857200710.1093/jnci/djk19617551145
|
|
5.
|
K AaboM AdamsP AdnittChemotherapy in
advanced ovarian cancer: four systemic meta-analysis of individual
patient data from 37 randomized trialsBr J
Cancer7814791487199810.1038/bjc.1998.7109836481
|
|
6.
|
AE TaylorE WiltsawME GoreLong-term
follow-up of the first randomized study of cisplatin versus
carboplatin for advanced epithelial ovarian cancerJ Clin
Oncol122066207019947931475
|
|
7.
|
JP PignonJ BourhisC DomangeL
DesignéChemotherapy added to locoregional treatment for head and
neck squamous cell carcinoma: three meta-analyses of updated
individual
dataLancet355949955200010.1016/S0140-6736(00)90011-010768432
|
|
8.
|
LH EinformSD WilliamsPT LoehrerEvaluation
of optimal duration of chemotherapy in favourable-prognosis
disseminated germ cell tumors: a Southeastern Cancer Study Group
ProtocolJ Clin Oncol738739119892465391
|
|
9.
|
D KaufmanD RaghavanM CarducciPhase II
trial of gemcitabine plus cisplatin in patients with metastatic
urothelial cancerJ Clin Oncol1819211927200010784633
|
|
10.
|
B RosenbergPlatinum complexes for the
treatment of cancer: why the research goes onCisplatin: Chemistry
and Biochemistry of a Leading Anticancer DrugB LippertVerlag
Helvetica Chemica ActaZurich3121999
|
|
11.
|
DM HayesE CritkovicRB GolbeyHigh dose
cis-platinum diammine dichloride: amelioration of renal toxicity by
mannitol
diuresisCancer3913721381197710.1002/1097-0142(197704)39:4%3C1372::AID-CNCR2820390404%3E3.0.CO;2-J856437
|
|
12.
|
CM SorensonA EastmanMechanism of
cis-diamminedichloroplatinum (II)-induced cytotoxicity: role of G2
arrest and DNA double-strand breaksCancer
Res484484448819883395999
|
|
13.
|
DR GandaraNA NahhasMD AdelsonRandomized
placebo-controlled multicenter evaluation of diethyldithiocarbamate
for chemoprotection against cisplatinum-induced toxicitiesJ Clin
Oncol134904961995
|
|
14.
|
I AranyRL SafirsteinCisplatin
nephrotoxicitySemin
Nephrol23460464200310.1016/S0270-9295(03)00089-513680535
|
|
15.
|
A TognoniF PensaF VairaA dose finding
study of carboplatin and gemcitabine in advanced non-small-cell
lung cancerJ
Chemother14296300200210.1179/joc.2002.14.3.29612120886
|
|
16.
|
BE JohnsonIntegration of new agents into
the treatment of advanced non-small-cell lung cancerAmerican
Society of Clinical Oncology Educational BookMC PerryR
GovindanLipincott Williams and WilkinsBaltimore3453562000
|
|
17.
|
GP StathopoulosM VeslemesN
GeorgatouPaclitaxel and vinorelbine combination in advanced
inoperable adenocarcinoma of the lung: a phase II studyAnticancer
Res2334793484200312926094
|
|
18.
|
GP StathopoulosJ DimitroulisD
AntoniouFront-line paclitaxel and irinotecan combination
chemotherapy in advanced non-small-cell lung cancer: a phase I–II
trialBr J Cancer93110611112005
|
|
19.
|
FV FosellaR DeVoreRN KerrRandomized phase
III trial of docetaxel versus vinorelbine or ifosfamide in patients
with advanced non-small-cell lung cancer previously treated with
platinum-containing chemotherapy regimensJ Clin
Oncol18235423622000
|
|
20.
|
GP StathopoulosM VeslemesN
GeorgatouFront-line paclitaxel-vinorelbine versus
paclitaxel-carboplatin in patients with advanced non-small-cell
lung cancer: a randomized phase III trialAnn
Oncol1510481055200410.1093/annonc/mdh26015205198
|
|
21.
|
P ComellaG FresciN PanzaRandomized trial
comparing cisplatin, gemcitabine and vinorelbine with either
cisplatin and gemcitabine or cisplatin and vinorelbine in advanced
non-small cell lung cancer: interim analysis of a phase III trial
of the Southern Italy Cooperative Oncology GroupJ Clin
Oncol18145114572000
|
|
22.
|
T BoulikasGP StathopoulosN VolakakisM
VougioukaSystemic lipoplatin infusion results in preferential tumor
uptake in human studiesAnticancer Res2530313039200516080562
|
|
23.
|
GP StathopoulosSK RigatosJ
StathopoulosLiposomal cisplatin dose escalation for determining the
maximum tolerated dose and dose-limiting toxicity: a phase I
studyAnticancer Res3013171321201020530446
|
|
24.
|
GP StathopoulosT BoulikasM
VougioukaLiposomal cisplatin combined with gemcitabine in
pretreated advanced pancreatic cancer patients: a phase I–II
studyOncol Rep15120112042005
|
|
25.
|
M KoukourakisA GiatromanolakiM
PitakoudisConcurrent liposomal cisplatin (lipoplatin),
5-fluorouracil and radiotherapy for the treatment of locally
advanced gastric cancer: a phase I–II studyInt J Radiol Oncol Biol
Phys78150155200920138443
|
|
26.
|
G KarpathiouE ArgianaA KoutsopoulosME
FroudarakisResponse of a patient with pleural and peritoneal
mesothelioma after second-line chemotherapy with lipoplatin and
gemcitabineOncology73426429200810.1159/00013680018523361
|
|
27.
|
FS FarhatK IbrahimJ KattanPreliminary
results of Phase II study of liposomal cisplatin-vinorelbine
combination as first-line treatment in HER2/neu negative metastatic
breast cancer (MBC)Proceedings of the ASCO Annual Meeting, abs.
313512009
|
|
28.
|
M MylonakisA AthanasiouN ZirasPhase II
study of liposomal cisplatin (lipoplatin) plus gemcitabine versus
cisplatin plus gemcitabine as first line treatment in inoperable
(stage IIIB/IV) non-small-cell lung cancerLung
Cancer68240247201010.1016/j.lungcan.2009.06.01719628292
|
|
29.
|
GP StathopoulosT BoulikasM
VougioukaPharmacokinetics and adverse reactions of a new liposomal
cisplatin (lipoplatin): phase I studyOncol
Rep13589595200515756428
|
|
30.
|
AB MillerB HoogstratenM StagnetReporting
results of cancer
treatmentCancer47207214198110.1002/1097-0142(19810101)47:1%3C207::AID-CNCR2820470134%3E3.0.CO;2-67459811
|
|
31.
|
P TherasseSG ArbuckEA EisenhowerNew
guidelines to evaluate the response to treatment in solid tumors
European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of CanadaJ Natl Cancer
Inst92205216200010.1093/jnci/92.3.205
|
|
32.
|
GP StathopoulosS RigatosJ StathopoulosS
BatziosLiposomal cisplatin in cancer patients with renal
failureProceedings of the ASCO Annual Meeting. abs. 70722011
|
